As of 2026-09-10, BRKR scores 41out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. BRKR trades at $53.56, 5% above the band ceiling.
BRKR scores 41 out of 100 on QNTM's five-factor model — a low-conviction reading — at 41 the factor profile is among the weaker names in the universe. Its strongest factor is value at 61 (solid), where it screens cheap on the model's valuation inputs, followed by momentum at 48. The weakest is sentiment at 20, where sentiment signals are working against it. Among Healthcare stocks it sits in the lower 31% of Healthcare names by composite.
On valuation, BRKR is priced near the top of its recent range — the rich end on the model's valuation read. The blended composite before the macro overlay was 43. Same-sector names the model rates nearby include HALO, THC, TGTX.
This is a descriptive factor read on BRKR, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where BRKR sits on the model's measures today, and can change as new data arrives.
QNTM’s descriptive fair-value band for BRKR runs $26.33–$50.97. Current price $53.56 sits 5% above the band ceiling. This is valuation context, not a price target.
QNTM rescores BRKR and ~1,400 other names every session. Track it, get notified the moment it crosses a conviction tier, and see the full signal history.
Start free →QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.